Literature DB >> 15865221

Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids.

Sarah E Ward1, Mona R Loutfy, Lawrence M Blatt, Katharine A Siminovitch, Jiabing Chen, Anna Hinek, Bryan Wolff, Dieu H Pham, Hassan Deif, Elizabeth A LaMere, Kevin C Kain, Gabriella A Farcas, Patti Ferguson, Mary Latchford, Gary Levy, Liasum Fung, James W Dennis, Enoch K Y Lai, Eleanor N Fish.   

Abstract

Severe acute respiratory syndrome (SARS), caused by a novel coronavirus, emerged in early 2003 as a major international health crisis. We report on serum cytokine levels, viral load and clinical parameters over the course of the disease in a cohort of nine adult SARS patients treated with steroids and interferon alfacon-1 at North York General Hospital in Toronto, Ontario. Considerable variation among SARS patients with respect to circulating viral load and patterns of SARS-CoV-evoked cytokine responses was recorded. No single cytokine profile was observed in all patients, yet serum concentrations of interferon (IFN)-gamma, interleukin (IL)-10, CXCL10, CCL5 and CXCL8 were found to be elevated above normal levels during the course of the disease in all patients. Expression levels for IL-10, IFN-gamma and CXCL10 consistently peaked within 4 days of peak viral load. IL-12p70, IL-4 and tumour necrosis factor-alpha concentrations were consistently highest within 5 days of peak viral load. These results suggest that elevated levels of inflammatory cytokines are sensitive correlates of disease severity, including lung abnormalities and viral load in serum, and may provide a tool for monitoring disease progression in affected individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865221

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  22 in total

1.  Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice.

Authors:  Nadine De Albuquerque; Ehtesham Baig; Xuezhong Ma; Jianhua Zhang; William He; Andrea Rowe; Marlena Habal; Mingfeng Liu; Itay Shalev; Gregory P Downey; Reginald Gorczynski; Jagdish Butany; Julian Leibowitz; Susan R Weiss; Ian D McGilvray; M James Phillips; Eleanor N Fish; Gary A Levy
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

2.  Murine hepatitis virus strain 1 as a model for severe acute respiratory distress syndrome (SARS).

Authors:  Nadine DeAlbuquerque; Ehtesham Baig; Max Xuezhong; Itay Shalev; M James Phillips; Marlena Habal; Julian Leibowitz; Ian McGilvray; Jagdish Butany; Eleanor Fish; Gary Levy
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

Review 3.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

4.  Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor.

Authors:  Chien-Te K Tseng; Cheng Huang; Patrick Newman; Nan Wang; Krishna Narayanan; Douglas M Watts; Shinji Makino; Michelle M Packard; Sherif R Zaki; Teh-Sheng Chan; Clarence J Peters
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

5.  Genetic determinants of mouse hepatitis virus strain 1 pneumovirulence.

Authors:  Julian L Leibowitz; Rajiv Srinivasa; Shawn T Williamson; Ming Ming Chua; Mingfeng Liu; Samantha Wu; Hyojeung Kang; Xue-Zhong Ma; Jianhua Zhang; Itay Shalev; Robert Smith; Melville J Phillips; Gary A Levy; Susan R Weiss
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

6.  Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2.

Authors:  Naoko Yoshikawa; Tomoki Yoshikawa; Terence Hill; Cheng Huang; Douglas M Watts; Shinji Makino; Gregg Milligan; Tehsheng Chan; Clarence J Peters; Chien-Te K Tseng
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 7.  Potential role of high mobility group box 1 in viral infectious diseases.

Authors:  Haichao Wang; Mary F Ward; Xue-Gong Fan; Andrew E Sama; Wei Li
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

Review 8.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Authors:  Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

9.  Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity.

Authors:  Lorena Vigón; Daniel Fuertes; Javier García-Pérez; Montserrat Torres; Sara Rodríguez-Mora; Elena Mateos; Magdalena Corona; Adolfo J Saez-Marín; Rosa Malo; Cristina Navarro; María Aranzazu Murciano-Antón; Miguel Cervero; José Alcamí; Valentín García-Gutiérrez; Vicente Planelles; María Rosa López-Huertas; Mayte Coiras
Journal:  Front Immunol       Date:  2021-05-26       Impact factor: 7.561

Review 10.  Immune heterogeneity in neuroinflammation: dendritic cells in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.